Affimed N.V. (AFMD)
After hours:
| Previous Close | 2.7100 |
| Open | 2.7100 |
| Bid | 2.9300 x 2200 |
| Ask | 3.1300 x 4000 |
| Day's Range | 2.7100 - 2.9750 |
| 52 Week Range | 2.2300 - 8.6400 |
| Volume | |
| Avg. Volume | 2,060,950 |
| Market Cap | 436.012M |
| Beta (5Y Monthly) | 2.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6590 |
| Earnings Date | Sept 06, 2022 - Sept 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.84 |
- GlobeNewswire
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitorsIn vivo studies of an AML murine model demonstrated anti-tumor efficacy; cynomolgus toxicology models showed pharmacodynamic activity with a well-tolerated safety profile suggestin
- Zacks
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and an increase in complete responses (CR) from 38%, reported in December, to 62% after a second cycle of therapy in 13 patients at the recommended phase 2 dose (RP2D) with encouraging signals on durabilityAFM24 monotherapy:
